keyword
MENU ▼
Read by QxMD icon Read
search

Ankylosing spondylitis treatment

keyword
https://www.readbyqxmd.com/read/28108800/impact-of-treatment-with-tnf-antagonists-on-total-cholesterol-in-patients-with-ankylosing-spondylitis-and-psoriatic-arthritis
#1
Jose Ramon Maneiro, Alejandro Souto, Juan J Gomez-Reino
The objective of the study was to analyze the impact of TNF antagonists (TNFa) on the total cholesterol and triglycerides on ankylosing spondylitis (AS) and psoriatic arthritis (PsA). In this single-centre observational study of AS and PsA patients, differences in triglyceride and total cholesterol levels and frequency of hypertriglyceridemia and hypercholesterolemia at 3 and 6 months were analysed in patients treated and not treated with TNFa. General estimation equations and linear regression analysis were used to investigate associations between disease activity and lipid levels and to identify predictors of change...
January 20, 2017: Clinical Rheumatology
https://www.readbyqxmd.com/read/28107237/evaluating-a-posterior-approach-for-surgical-treatment-of-thoracolumbar-pseudarthrosis-in-ankylosing-spondylitis
#2
Ting Wang, Dechun Wang, Yanan Cong, Chuqiang Yin, Shuzhong Li, Xiaoliang Chen
STUDY DESIGN: Retrospective study of a posterior approach for surgical treatment of thoracolumbar pseudarthrosis in ankylosing spondylitis (AS). OBJECTIVE: The aim of the current study was to report the surgical results of symptomatic thoracolumbar pseudarthrosis in AS through a posterior approach. SUMMARY OF BACKGROUND DATA: Spinal pseudarthrosis is a well-known complication in AS. The condition may complicate with mechanical back pain, spinal deformity, and sometimes neurological deficits...
February 2017: Clinical Spine Surgery
https://www.readbyqxmd.com/read/28103205/is-the-use-of-agile-patency-capsule-prior-to-videocapsule-endoscopy-useful-in-all-patients-with-spondyloarthritis
#3
Andrada Gheorghe, Denise Carmen Mihaela Zahiu, Theodor Alexandru Voiosu, Bogdan Radu Mateescu, Mihail Radu Voiosu, Mihai Rimbaş
BACKGROUND AND AIMS: As already known, spondyloarthritis patients present a striking resemblance in intestinal inflammation with early Crohn's disease. Moreover, the frequent use of nonsteroidal anti-inflammatory drugs is an important part of their treatment. Both conditions could lead to intestinal stenoses. Therefore we proposed to investigate the usefulness of the patency capsule test in patients with spondyloarthritis. MATERIAL AND METHODS: 64 consecutive patients (33 males; mean age 38 ± 11 years) that fulfilled the AMOR criteria for seronegative spondyloarthropathy (59...
January 18, 2017: Romanian Journal of Internal Medicine, Revue Roumaine de Médecine Interne
https://www.readbyqxmd.com/read/28101910/a-practical-approach-to-vaccination-of-patients-with-autoimmune-inflammatory-rheumatic-diseases-in-australia
#4
REVIEW
Peter Kk Wong, Hanish Bagga, Claire Barrett, Paddy Hanrahan, Doug Johnson, Amel Katrib, Karin Leder, Mona Marabani, Peta Pentony, John Riordan, Ray White, Laurel Young
Autoimmune inflammatory rheumatic diseases (AIIRD) such as rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (AS) are often complicated by infection, which results in significant morbidity and mortality. The increased risk of infection is probably due to a combination of immunosuppressive effects of the AIIRD, comorbidities, and the use of immunosuppressive conventional synthetic disease modifying anti-rheumatic drugs (DMARDS) and more recently, targeted synthetic DMARDS and biologic DMARDS which block specific pro-inflammatory enzymes, cytokines or cell types...
January 19, 2017: Internal Medicine Journal
https://www.readbyqxmd.com/read/28099816/new-treatment-options-and-emerging-drugs-for-axial-spondyloarthritis-biological-and-targeted-synthetic-agents
#5
Eric Toussirot
Ankylosing spondylitis (AS) and axial spondyloarthritis (ax SpA) are chronic inflammatory diseases mainly involving the axial skeleton. Pharmacological treatments for AS and ax SpA usually include local glucocorticoid injections, NSAIDs and anti-TNFa agents. Since around 30% to 40% of patients are non responders or intolerant to anti-TNFa agents, we need new therapeutic options for AS and ax SpA. Areas covered: This review describes the new biological agents that can be used or are in development for AS or ax SpA as well as emerging synthetic targeted drugs...
January 18, 2017: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/28095262/biosimilars-in-inflammatory-bowel-disease-accumulating-clinical-evidence
#6
Sean McConachie, Sheila M Wilhelm, Pramodini B Kale-Pradhan
Biologic antagonists to tumor necrosis factor alpha (TNF- α) are effective medications and have become well established in the treatment of both Crohn's disease and ulcerative colitis. Biosimilar medications, which are medications deemed to be equivalent to reference biologic products in terms of clinical effectiveness, safety, pharmacokinetic analysis, and immunogenicity, have now been approved in inflammatory bowel diseases (IBD) based on indication exploration from clinical data in alternate disease states...
January 17, 2017: Expert Review of Clinical Pharmacology
https://www.readbyqxmd.com/read/28087505/2016-update-of-the-asas-eular-management-recommendations-for-axial-spondyloarthritis
#7
Désirée van der Heijde, Sofia Ramiro, Robert Landewé, Xenofon Baraliakos, Filip Van den Bosch, Alexandre Sepriano, Andrea Regel, Adrian Ciurea, Hanne Dagfinrud, Maxime Dougados, Floris van Gaalen, Pál Géher, Irene van der Horst-Bruinsma, Robert D Inman, Merryn Jongkees, Uta Kiltz, Tore K Kvien, Pedro M Machado, Helena Marzo-Ortega, Anna Molto, Victoria Navarro-Compàn, Salih Ozgocmen, Fernando M Pimentel-Santos, John Reveille, Martin Rudwaleit, Jochen Sieper, Percival Sampaio-Barros, Dieter Wiek, Jürgen Braun
To update and integrate the recommendations for ankylosing spondylitis and the recommendations for the use of tumour necrosis factor inhibitors (TNFi) in axial spondyloarthritis (axSpA) into one set applicable to the full spectrum of patients with axSpA. Following the latest version of the European League Against Rheumatism (EULAR) Standardised Operating Procedures, two systematic literature reviews first collected the evidence regarding all treatment options (pharmacological and non-pharmacological) that were published since 2009...
January 13, 2017: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/28079501/clinical-efficacy-of-oral-alendronate-in-ankylosing-spondylitis-a-randomised-placebo-controlled-trial
#8
Lucy Coates, Jonathan C Packham, Paul Creamer, Sarah Hailwood, Ashley S Bhalla, Kuntal Chakravarty, Diamuid Mulherin, Gordon Taylor, Derek L Mattey, Ashok K Bhalla
OBJECTIVES: A prospective, double blind, randomised, placebo controlled trial over 2 years was performed to test the efficacy of alendronate, an oral aminobisphosphonate, in improving symptoms and arrest disease progression in patients with mild to severe ankylosing spondylitis (AS). METHODS: 180 patients with AS were randomised to receive weekly alendronate 70 mg or placebo (1:1 randomisation). BAS-G was the primary outcome measure with Bath indices as secondary outcomes...
January 4, 2017: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/28043168/plasma-levels-of-pentraxin-3-in-patients-with-spondyloarthritis
#9
Renato Nisihara, Thelma L Skare, João Otávio Zeni, Henrique Rasera, Karita Lidani, Iara Messias-Reason
CONTEXT: Determining the disease's inflammatory activity in Spondyloarthritis (SpA) is difficult although very important as it is this that drives treatment. OBJECTIVE: To investigate if plasma PTX3 (Pentraxine-3) could act as an inflammatory marker in SpA. METHODS: Eighty one SpA patients (11 with psoriatic arthritis or PsoA and 70 with Ankylosing Spondylitis or AS) and 90 gender and age paired controls were studied for plasma PTX3 levels by ELISA...
January 3, 2017: Biomarkers: Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals
https://www.readbyqxmd.com/read/28035438/should-axial-spondyloarthritis-without-radiographic-changes-be-treated-with-anti-tnf-agents
#10
REVIEW
Andrew Keat, Alexander N Bennett, Karl Gaffney, Helena Marzo-Ortega, Raj Sengupta, Tamara Everiss
A spectrum of disease extends beyond the rigid confines of ankylosing spondylitis (AS). Axial spondyloarthritis (axSpA) encompasses non-radiographic axSpA (nr-axSpA) in individuals without established radiographic changes but with other clinical/imaging axSpA features and AS in those with definite sacroiliac joint changes on pelvic X-rays. A broad consensus about the management of nr-axSpA is emerging among clinicians, but the evidence base remains open to question. To explore whether nr-axSpA and AS should be treated similarly, we examined the literature on their prevalence, natural history, disease burden, and treatment...
December 29, 2016: Rheumatology International
https://www.readbyqxmd.com/read/28007105/outcomes-and-complications-of-excimer-laser-surgery-in-patients-with-collagen-vascular-and-other-immune-mediated-inflammatory-diseases
#11
Julie M Schallhorn, Steven C Schallhorn, Keith A Hettinger, Jan A Venter, Martina Pelouskova, David Teenan, Stephen J Hannan
PURPOSE: To assess refractive and visual outcomes and postoperative complications in a large number of patients with well-controlled collagen vascular and other immune-mediated inflammatory diseases. SETTING: Optical Express, Glasgow, United Kingdom. DESIGN: Retrospective case series. METHODS: The files were reviewed of patients who had collagen vascular and other immune-mediated inflammatory diseases and who had excimer laser surgery between 2008 and 2015...
December 2016: Journal of Cataract and Refractive Surgery
https://www.readbyqxmd.com/read/27999312/a-possible-role-of-intestinal-microbiota-in-the-pathogenesis-of-ankylosing-spondylitis
#12
REVIEW
Lianjun Yang, Liping Wang, Xin Wang, Cory J Xian, Hai Lu
Ankylosing spondylitis (AS) is a chronic inflammatory disease primarily affecting the sacroiliac joints and the spine, for which the pathogenesis is thought to be a result of the combination of host genetic factors and environmental triggers. However, the precise factors that determine one's susceptibility to AS remain to be unraveled. With 100 trillion bacteria residing in the mammalian gut having established a symbiotic relation with their host influencing many aspects of host metabolism, physiology, and immunity, a growing body of evidence suggests that intestinal microbiota may play an important role in AS...
December 17, 2016: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/27984714/il-17-blockade-in-psoriasis
#13
Patrick R Burkett, Vijay K Kuchroo
IL-17A both directly induces and synergizes with other cytokines to promote autoimmune tissue inflammation. Secukinumab and ixekizumab are monoclonal antibodies (mAb) that inhibit interleukin-17A. These two agents were recently approved for treatment of psoriasis, and secukinumab is also approved for treatment of two spondyloarthropathies, psoriatic arthritis and ankylosing spondylitis.
December 15, 2016: Cell
https://www.readbyqxmd.com/read/27981820/aseptic-hla-b27-positive-spondylodiscitis-decreased-18f-fdg-uptake-after-etanercept-treatment
#14
M Benucci, A Damiani, A Arena, M Infantino, M Manfredi, F Li Gobbi
We observed a 69-year old man suffering from HLA B27 ankylosing spondylitis with persistent night back pain. 18F-FDG-PET/CT showed an increased metabolism at the level of the spinal space of L2-L3, L3-L4 with increased uptake compatible with spondylodiscitis. He started therapy with etanercept 50 mg/week. After six months of treatment repeated testing showed no uptake of the discs and vertebral bodies.
December 16, 2016: Reumatismo
https://www.readbyqxmd.com/read/27971501/long-term-improvements-in-workplace-and-household-productivity-and-social-participation-over-4-years-of-certolizumab-pegol-treatment-in-patients-with-axial-spondyloarthritis-including-ankylosing-spondylitis-and-non-radiographic-axial-spondyloarthritis
#15
D van der Heijde, J Braun, M Rudwaleit, R Landewé, O Purcaru, A Kavanaugh
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27971471/a-cost-effectiveness-analysis-of-biosimilar-infliximab-inflectra-%C3%A2-for-the-treatment-of-ankylosing-spondylitis-in-nine-european-countries
#16
F Rencz, Brodszky, M Péntek, L Gulacsi, P Baji
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27971467/cost-effectiveness-analysis-of-different-biologic-agents-for-ankylosing-spondylitis-treatment-in-russia
#17
D Fedyaev, E V Derkach
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27971456/a-cost-per-responder-analysis-of-secukinumab-vs-adalimumab-based-on-a-matching-adjusted-indirect-comparison-for-the-treatment-of-ankylosing-spondylitis-from-a-german-payer-perspective
#18
P Gunda, A Kandhare, E Nikoglou, S M Jugl, J Kneidl, K Neidhardt
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27971443/budget-impact-model-of-secukinumab-in-the-treatment-of-ankylosing-spondylitis-as-and-with-psoriatic-arthritis-psa-in-italy
#19
G L Colombo, S Di Matteo, G M Bruno, M C Valentino, M Oselin, A Roccia
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27964793/lung-involvement-in-inflammatory-rheumatic-diseases
#20
REVIEW
Clive Kelly, Kundan Iqbal, La'ali Iman-Gutierrez, Phil Evans, Kanchan Manchegowda
This chapter describes the involvement of the lung in systemic inflammatory joint disease (IJD) with a particular focus on rheumatoid arthritis, although the topics of pulmonary involvement in ankylosing spondylitis and psoriatic arthritis are also addressed. Interstitial lung disease is the most lethal pulmonary complication of IJD and the chapter describes recent advances in both our understanding of this complication and the therapeutic options that offer real hope for improved outcomes. Although less well recognised, airways disease is just as common and its association with IJD is described in some detail, with a section devoted to the recent surge in interest in bronchiectasis...
October 2016: Best Practice & Research. Clinical Rheumatology
keyword
keyword
53915
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"